Member Info for rivaldo

I should add that RNWH are in the middle of an extensive period of meeting investors - two weeks of touring the City, the North and Scotland, which is more than they usually due at the interim stage. The current price looks cheap to me. I wouldn't be surprised to see more institutional buying coming in after this series of presentations.

I attended a presentation from RNWH yesterday. Here's a few jottings from the meeting - and the interim presentation can be seen here: Http://www.renewholdings.com/investors/reports-and-presentations/ - the profit split is normally 47% or 48%/52% for H1/H2. By implication, with 13.31p EPS in H1 alone RNWH is extremely well placed to meet - and possibly beat - the two forecasts of 27.5p EPS and 27.2p EPS to 30th September - RNWH are aiming short-term to get operating margins up to 4.5% from H1's 4%. This alone would add another £2.7m to profits based on H1's annualised revenue - the 18% dividend rise in H1 suggests an 8p dividend for the year - RNWH have examined a number of acquisitions. These often take years to come to fruition at the right time and price. More are on the way, but timelines are impossible to predict. The CEO was asked about the problematic telecoms and gas acquisitions, and he replied with optimism about them both, noting that consolidation in telecoms and the slow pace of gas contract awards couldn't be predicted and are being overcome by adapting or stepping up the pace - RNWH pay their supply chain one week AFTER they get paid, with obvious cash flow benefits. The largest customer pays in 28 days, with the majority on 28-40 days. The negative £4.2m working capital movement in H1 should entirely reverse in H2 to be neutral overall - of the £3billion nuclear decommissioning programme to be spent, 90% will be at sites where RNWH work (14 of the 17 NDA sites), and 70% will be at Sellafield, where RNWH have a VERY strong position via Shepley Engineers as the largest contractor with 11 frameworks - RNWH are the sole provider on the £30m Magnox nuclear framework at 10 sites, with potential for later decommissioning work - 3 new nuclear opportunities are being actively developed, including Moorside, which is adjacent to Sellafield, so very favourable for RNWH - Shepley's new appointment to the Courtyards framework at the Palace of Westminster is a biggie imo - at some point Westminster will have to be entirely overhauled, and this will cost £billions - the average contract value for large infrastructure contracts is £300k, so very low risk of material overruns - RNWH had no infrastructure work in Scotland 4 years ago. It displaced the incumbent, and has won £50m of work If anything else occurs to me I'll post it later, but if any other attendees are watching I'm happy to accept corrections!

My problem with ZYT's current valuation is nervousness about them meeting expectations this year. ZYT made 9.6p EPS in this H1, so that leaves them having to make 16.3p EPS in H2 just to meet the 25.9p EPS forecast. They made 16p EPS in last year's H2, so it's certainly possible. But this year's H1 was characterised by a big decline in the traditional business sales of glass displays and filter products. So ZYT had to run fast just to stand still. Since touch product sales only increased 5% over last year this meant group profits improved overall given the higher touch margins, but not enough to make a big difference. The outlook suggest a continuation in H2, with traditional business again slipping and being outweighed by touch. This year's forecast/expectations have perhaps been overinflated by last year's exceptional H2. It's a long time until the next trading update in October, so I'll probably stay out until confirmation at that point that H2 has - or hasn't - been able to achieve a similar improvement in H2 to last year.

Finncap retain their Buy and 170p target: Http://www.ftsenews.co.uk/2016/05/17/finncap-reiterated-carclo-plc-loncar-as-buy/ And Peel Hunt retain their Buy and 165p target: Http://www.ftsenews.co.uk/2016/05/17/peel-hunt-retained-carclo-plc-loncar-as-buy/

SCH's cash pile amounts to around 53p per share. That leaves an "EV" of around 179p per share, against for example Shore Capital's forecast of 13.23p EPS this year and 15.9p EPS next year. With 8.22p and 9.04p dividends. And the likelihood of earnings-enhancing acquisitions. Canaccord have a 320p price target, and Numis go for 350p. Last week's AGM statement was exceedingly strong.

WJG have been tipped today in Shares Mag - full page review, but subscriber-only: Http://www.sharesmagazine.co.uk/article/grab-watkin-jones-for-income "Grab Watkin Jones for income Student housing specialist’s business model should facilitate handsome dividends 26 May 2016 Take a stake in student housing developer Watkin Jones (WJG:AIM) ahead of its maiden half year results on 9 June. The company is a really interesting take on the property market where developments tend to be pre-sold and forward funded by the buyer. That makes the £285 million cap an asset light, low working capital business. Its business model has ... "

Shares Mag today say they're "big fans" of ETO in a review of the results, noting the improved free cash flow and reduction in debt. In particular, there's an interview with the CEO where he notes that the acquisition of the larger stake in Peppa has been transformative. ETO can now enable faster brand commercialisation with many new branding opportunity conversations initiated. There are also hints at a Peppa Pig film, and also perhaps additional Peppa theme parks to follow the Paultons Park success.

Unusually - and as we approach the prelims, presumably early next week in line with prior years - you can buy up to 4k shares online at 447.45p (essentially the mid-price).

You can only buy 50k maximum at the full 14.5p offer, but you can sell 150k at a premium at 13.78p.

The market likes the results, and Zeus Capital agree the results are good and say as follows this morning: "FY15 results show that CentralNic has delivered revenue of £10.4m (+71%), adj. EBITDA of £3.3m (+47%) and adj. PBT of £3.0m (+113%), with growth in both revenues and profits experienced across all three group divisions. In our view, the business is well positioned for continued growth, thanks to a growing and impressive track record of diversification and M&A. When CentralNic came to the public market in September 2013, its primary business activity was as an owner-operator of second level domains and as a “Wholesaler” of various other top level domain names (“TLDs”), responsible for operating the complete technical backend for a number of TLDs. It also had guarantees to operate, as a wholesaler, 26 new domain launches. The CentralNic business of today is in a significantly stronger position within the domain industry, having proven itself to be the leading Wholesaler of new gTLDs and also as a result of management having successfully moved the business up the value chain via clever M&A and investment, with the creation of two new operating divisions; Retail and Enterprise.  Well positioned for impressive growth over the forecast period. Net sales are expected to increase from £6.1m in FY14A to £26.5m in FY17E, a CAGR of some 63%, and EBITDA from £1.7m in FY14A to £7.6m in FY17E, a CAGR of 64%. In our view, the current valuation does not reflect the progress made to date by management nor the opportunities that should arise for the business to establish itself as a major player in the sector over the medium term. "

Results are out and look good at first glance. In particular, the £2.95m adjusted PBT is well ahead of Peel Hunt's forecast £2.71m: Http://www.investegate.co.uk/centralnic-group-plc--cnic-/rns/final-results/201605250700101930Z/ CNIC don't publish an adjusted EPS figure unfortunately. They "remain confident in the outlook for 2016", and there's lots of positivity going forward. The Instra acquisition in January should enable CNIC to make strong advances towards this year's forecast of 4.02p EPS.

Trading in line with now historic 7p EPS expectations, so at around 69p this is looking pretty cheap imho. Especially when forecasts are for above 9p EPS this year - and with a dividend to add to the attractions.

Cracking update. Can't ask for more - and great to see the succession planning in place with Steve Brown moving up to CEO and TB becoming Chairman. The outlook looks great: "the encouragingly strong start means we are increasingly confident about our likely performance for the year"

Excellent all round - with "Expected revenue for H2 secured" we can already be sure that the full results for the year will be good, and likely at least in line with expectations. And possibly better. RNWH now expect to have net cash by the year end, so there will surely be further earnings-enhancing acquisitions soon. All divisions are thriving, with the exception of the small gas division where the potential remains huge, and telecoms where activity will probably pick up after last year's industry consolidation settles down. I'm a very happy holder. Lots more to come over time here imho.

Pretty decent considering (a) the down year for the Film division, and (b) the share price, which has factored in the worst. 19.4p adjusted EPS is right at the top of expectations, which range from 18.2p to 19.5p. The outlook seems very positive, still aiming at doubling the size of the business. Free cash flows increased nicely for the year, and overall net debt was £44m less at the year end, with all the rights issue monies being used on acquisitions etc. With Film looking much better this year, and Family and TV continuing to thrive, perhaps we can now see a route back to a 250p-300p share price.

Excellent trading update showing historic results in line with 1.5p EPS expectations: http://www.investegate.co.uk/scientific-dig-imag--sdi-/rns/trading-update/201605240700060363Z/ Finncap this morning also forecast £0.8m adjusted PBT and £1m net cash against a £6m m/cap. For this year they expect £1.1m adjusted PBT and 1.6p EPS. They have a 29p target price. At an 11p share price SDI look extremely cheap AND have a very sound Balance Sheet. New(ish) management have now transformed the company, and Sentek has brought in good recurring revenues and increased profitability. I'd anticipate further acquisitions soon given the cash pile. This is just the start of the journey imho. There could be a long way to go.

Big trades today - 1.47m shares have gone through at 130p. Hopefully the clearance of an overhang....and an immediate series of ticks upwards suggests perhaps this is the case.

Nice mention for GMAA here: http://tinyurl.com/h2psram "Among Oxford’s other major tenants is Gama Aviation, which merged with Oxford-based Hangar 8, adding significant large-jet maintenance, repair and overhaul (MRO) capability. The business blending process began at the start of last year, and is now complete. The enlarged Gama continues on both organic and acquisitive growth strategies, seeking to add more aircraft types to its authorized MRO portfolio and to expand its AOG (aircraft on ground) response capability. The Oxford base figures prominently in these plans..." It's encouraging that the article also states: "London Oxford Airport (LOA) reports that its traffic has risen 8.3 percent in the last quarter, an encouraging sign following the European business aviation peak in 2012 and a figure that places it in the top 10 of recent growth across European airports over the same period." All the developments at the airport listed in the article should bring in further business for GMAA.

Here's a good interview with the CEO which hasn't been posted and which again shows not only growing confidence re CD4, but also global ambitions for the core business: Http://www.heraldscotland.com/business/14444673.Sales_growth_of_food_intolerance_kits_fuels_overseas_ambitions_for_Omega/ "Sales growth of food intolerance kits fuels overseas ambitions for Omega 22 Apr 2016 / Victoria Masterson OMEGA Diagnostics, the Clackmannanshire company that produces tests for allergies, food intolerance and infection diseases, said it was making progress on its long-awaited HIV test and that strong growth in its food intolerance business could fuel growth in China, India and North America. “We’re getting close to a final product but we’ve still got some work to do,� said chief executive Andrew Shepherd of the portable HIV test, which is being modified to withstand very hot temperatures in sub-Saharan countries. “We’re up to 32 degrees, so it’s now just getting that test to work up to 35 degrees. It still has a great demand, because there is no CD4 test that can go down to village levels or clinics in Africa.� CD4 cells are a type of white blood cell that fight infection and indicate the health of a person’s immune system. In a trading update, Omega said its food Intolerance business – which sells a kit used by nutritionists and dieticians to test for 59 food intolerances and a lab test against 220 foods – had achieved its targeted double-digit revenue growth in the period, up 19 per cent to £7.1 million. However, its allergy business in Germany continued to decline as it saw a reduction in buying levels, hit by increased competition. Results for the year to 31 March 2016 are expected to be in line with expectations, with revenues 6 per cent ahead of last year at £12.7m and adjusted pre-tax profits in the range of £1.2m to £1.3m. The company said it had identified a ‘clear organic growth strategy’ for the next three to five years. “We’re pushing at a market that’s still developing,� said Mr Shepherd, who founded the business in 1987. “We’re not doing a lot in China at the moment but that’s a market that’s growing very quickly. We recently got our products into India through our Indian subsidiary and that’s another market with the potential for high growth. Another potential market is North America, were we’re doing very little at the moment. So there are a lot of good product markets out there and we’re very confident that

A date for your diary - Equity Development have arranged a presention by BLTG (and by KWS, which I also own) on 28th June: Https://www.eventbrite.co.uk/e/equity-development-investor-forum-june-2016-tickets-25576342529?ref=ebtn